WuXi Biologics Earns Top 1% Ranking in S&P Global Sustainability Yearbook for Third Year

Reuters

2025/05/19

WuXi Biologics Earns Top 1% Ranking in S&P Global Sustainability Yearbook for Third Year

WuXi Biologics (Cayman) Inc., a global Contract Research, Development, and Manufacturing Organization (CRDMO), announced its inclusion in the 2025 S&P Global Sustainability Yearbook (China Edition) for the third consecutive year. The announcement was made at the S&P Global Sustainable1 forum in Shenzhen on May 13, 2025. WuXi Biologics achieved a Corporate Sustainability Assessment $(CSA)$ score ranking in the top 1%, securing its place in both the Global Sustainability Yearbook and the China Edition. The Sustainability Yearbook recognizes companies excelling in corporate sustainability within their industries. WuXi Biologics' CEO and Chairman of the ESG Committee, Dr. Chris Chen, stated that the inclusion reflects the company's continued commitment to enhancing sustainability performance and promoting responsible practices throughout the value chain.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics (Cayman) Inc. published the original content used to generate this news brief on May 19, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2536506081"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2536506081\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2536506081?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-19 17:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2536506081","market":"us","top_or_hot":-1,"title":"WuXi Biologics Earns Top 1% Ranking in S&P Global Sustainability Yearbook for Third Year","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      WuXi Biologics Earns Top 1% Ranking in S&amp;P Global Sustainability Yearbook for Third Year\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        WuXi Biologics (Cayman) Inc., a global Contract Research, Development, and Manufacturing Organization (CRDMO), announced its inclusion in the 2025 S&amp;P Global Sustainability Yearbook (China Edition) for the third consecutive year. The announcement was made at the S&amp;P Global Sustainable1 forum in Shenzhen on May 13, 2025. WuXi Biologics achieved a Corporate Sustainability Assessment <a href=\"https://laohu8.com/S/CSA\">$(CSA)$</a> score ranking in the top 1%, securing its place in both the Global Sustainability Yearbook and the China Edition. The Sustainability Yearbook recognizes companies excelling in corporate sustainability within their industries. WuXi Biologics' CEO and Chairman of the ESG Committee, Dr. Chris Chen, stated that the inclusion reflects the company's continued commitment to enhancing sustainability performance and promoting responsible practices throughout the value chain.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/WXIBF\">Wuxi Biologics (Cayman) Inc</a>. published the original content used to generate this news brief on May 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>WuXi Biologics Earns Top 1% Ranking in S&P Global Sustainability Yearbook for Third Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWuXi Biologics Earns Top 1% Ranking in S&P Global Sustainability Yearbook for Third Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-19 17:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      WuXi Biologics Earns Top 1% Ranking in S&amp;P Global Sustainability Yearbook for Third Year\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        WuXi Biologics (Cayman) Inc., a global Contract Research, Development, and Manufacturing Organization (CRDMO), announced its inclusion in the 2025 S&amp;P Global Sustainability Yearbook (China Edition) for the third consecutive year. The announcement was made at the S&amp;P Global Sustainable1 forum in Shenzhen on May 13, 2025. WuXi Biologics achieved a Corporate Sustainability Assessment <a href=\"https://laohu8.com/S/CSA\">$(CSA)$</a> score ranking in the top 1%, securing its place in both the Global Sustainability Yearbook and the China Edition. The Sustainability Yearbook recognizes companies excelling in corporate sustainability within their industries. WuXi Biologics' CEO and Chairman of the ESG Committee, Dr. Chris Chen, stated that the inclusion reflects the company's continued commitment to enhancing sustainability performance and promoting responsible practices throughout the value chain.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/WXIBF\">Wuxi Biologics (Cayman) Inc</a>. published the original content used to generate this news brief on May 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999002463.SGD","symbol_name":"LionGlobal China Growth SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250519:nNDL4Wb5n1:1","article_id":"2536506081","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2536506081","pubTimestamp":1747645363,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"WuXi Biologics  Inc., a global Contract Research, Development, and Manufacturing Organization , announced its inclusion in the 2025 S&P Global Sustainability Yearbook  for the third consecutive year. The announcement was made at the S&P Global Sustainable1 forum in Shenzhen on May 13, 2025. WuXi Biologics achieved a Corporate Sustainability Assessment  score ranking in the top 1%, securing its place in both the Global Sustainability Yearbook and the China Edition. The Sustainability Yearbook recognizes companies excelling in corporate sustainability within their industries. WuXi Biologics' CEO and Chairman of the ESG Committee, Dr. Chris Chen, stated that the inclusion reflects the company's continued commitment to enhancing sustainability performance and promoting responsible practices throughout the value chain.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this A","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999002463.SGD":"LionGlobal China Growth SGD","LU1688375341.USD":"贝莱德中国灵活股票基金","BK1576":"医药外包概念","LU1720050803.USD":"安联全方位中国股票基金","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","LU0181495838.USD":"施罗德新兴亚洲A Acc","BK1610":"ETF&股票定投概念","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0052750758.USD":"富兰克林中国基金A Acc","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","02269":"药明生物","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","LU0051755006.USD":"摩根大通中国A (dist)","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","BK1521":"挪威政府全球养老基金持仓","LU0140636845.USD":"施罗德大中华区股票A Acc","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU0823426480.USD":"法巴中国股票经典Dis","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU0823426308.USD":"法巴中国股票基金","BK1589":"北水核心资产","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","BK1141":"生命科学工具和服务","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","LU0359201612.USD":"贝莱德中国基金A2","SG9999002562.SGD":"LionGlobal Asia Pacific SGD","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD"},"translate_title":"药明生物连续第三年在标普全球可持续发展年鉴中排名前1%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":0.9},"content_text":"WuXi Biologics Earns Top 1% Ranking in S&P Global Sustainability Yearbook for Third Year\n    \n\n        WuXi Biologics (Cayman) Inc., a global Contract Research, Development, and Manufacturing Organization (CRDMO), announced its inclusion in the 2025 S&P Global Sustainability Yearbook (China Edition) for the third consecutive year. The announcement was made at the S&P Global Sustainable1 forum in Shenzhen on May 13, 2025. WuXi Biologics achieved a Corporate Sustainability Assessment $(CSA)$ score ranking in the top 1%, securing its place in both the Global Sustainability Yearbook and the China Edition. The Sustainability Yearbook recognizes companies excelling in corporate sustainability within their industries. WuXi Biologics' CEO and Chairman of the ESG Committee, Dr. Chris Chen, stated that the inclusion reflects the company's continued commitment to enhancing sustainability performance and promoting responsible practices throughout the value chain.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics (Cayman) Inc. published the original content used to generate this news brief on May 19, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}